Accelerated bookbuild offering - Joint Global Coordinator and Joint Bookrunner Mithra
Kempen is pleased to announce the successful EUR 77.5 million capital increase via an accelerated bookbuild offering by Mithra
Transaction highlights
- The capital increase comprised 2.7m new shares representing 7.6% of Mithra’s pre-deal outstanding share capital, at a placement price of EUR 29.00 per share, generating EUR 77.5 million gross proceeds and representing the largest amount of money raised in an accelerated bookbuild offering this year for any European non-NASDAQ listed biotech company
- Indications of interest received during a market sounding exercise with US and European life sciences specialist and generalist investors provided comfort to launch the transaction at a base size of EUR 60 million with potential to upsize
- The accelerated bookbuilding process generated strong demand from investors, on the back of which the deal size was upsizedto EUR 77.5 million with a well covered orderbook
- The top ten investors in the orderbook are allocated c.77% of the deal
- Transaction proceeds are envisaged to be used to fund clinical development, give the company increased strategic and financial flexibility to further progress partnering discussions for the commercialization of Estelle and (co)development of Donesta and fund general corporate purposes
- Last year, Kempen advised Mithra in its EUR 26.1 million capital increase via which c.3.1 million new shares were issued at a placement price of EUR 8.40 each
Company description
Mithra Pharmaceuticals is a company focused on the development, manufacturing and commercialisation of drugs and generic products dedicated to Women’s Health. Mithra specialises in four different domains: contraception and fertility, menopause and osteoporosis, gynecological infections and female cancers. Its two lead development candidates Estelle and Donesta are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. The company is headquartered in Liège, Belgium
Contact
Read more on:
Transactions
No transactions found
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Initial Public Offering
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
US public offering
US public offering
US public offering
Sale to
Block trade in Boskalis shares
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Accelerated bookbuild offering
Public offer for
Fundraise
Public offer by German ADLER Real Estate
for Israeli
Sale of Dynamic Portfolios
Accelerated bookbuild offering
Public offer by German Vonovia
Accelerated bookbuild offering
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Sale of 3 German residential portfolios by Angelo Gordon
to consortium of buyers
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue
